ASCO Annual Meeting: GU Cancer

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

Durvalumab plus BCG maintained overall survival and quality of life in high-risk NMIBC at 5 years.

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

LY4052031 demonstrated promising clinical activity after disease progression on enfortumab vedotin in metastatic urothelial carcinoma.

Adjuvant durvalumab plus tremelimumab significantly improved DFS vs active monitoring in both high- and intermediate-risk resected RCC.

GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.

Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.

Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Niraparib plus abiraterone acetate and prednisone improved rPFS vs abiraterone acetate and prednisone and placebo in patients with mCSPC with alterations in HRR genes.

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.